InterMune shares jump as Boehringer's rival drug shows mixed results

[riky]

InterMune shares jump as Boehringer's rival drug shows mixed results

Shares of InterMune Inc rose as much as 17 percent on Friday after data showed German drugmaker Boehringer Ingleheim's rival drug had mixed results in late-stage trials. Data from two late-stage trials of Boehringer's nintedanib showed the drug improved patients' lung function, but one trial fell short of meeting its key secondary goals of improving overall health and delaying a disease flare up. Nintedanib and InterMune's pirfenidone are aimed at treating idiopathic pulmonary fibrosis (IPF) â€" an irreversible condition that leads to progressive loss of lung function due to scarring, which hinders a lung's ability to absorb oxygen. InterMune recently completed a late-stage trial of pirfenidone, which showed that after a year of treatment 16.5 percent of patients taking the drug experienced disease progression, around half the level of those using a placebo.

Source: You are not allowed to view links. Register or Login